Evidence map›Paper›PMID 34734369›Full record

ReviewJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2022

The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.

Lingxuan An, Ulrich Wirth, Dominik Koch, Malte Schirren, Moritz Drefs, Dionysios Koliogiannis, Hanno Nieß, Joachim Andrassy, Markus Guba, Alexandr V Bazhin and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 1 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 1 synthesis or guideline pooled it, 233 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Journal of traditional and complementary medicine · 2026
    Article
  6. International journal of molecular sciences · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. DietaryAnimals : an open access journal from MDPI · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  19. Article
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lingxuan AnDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Ulrich WirthDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Dominik KochDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Malte SchirrenDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Moritz DrefsDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Dionysios KoliogiannisDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Hanno NießDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Joachim AndrassyDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Markus GubaDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Alexandr V BazhinDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Jens WernerDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany.
Florian KühnDepartment of General, Visceral and Transplant Surgery, University Hospital of LMU Munich, Marchionini Str. 15, Munich, Germany. Florian.Kuehn@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-9830-3015
LMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatosteatosis is the earliest stage in the pathogenesis of nonalcoholic fatty (NAFLD) and alcoholic liver disease (ALD). As NAFLD is affecting 10-24% of the general population and approximately 70% of obese patients, it carries a large economic burden and is becoming a major reason for liver transplantation worldwide. ALD is a major cause of morbidity and mortality causing 50% of liver cirrhosis and 10% of liver cancer related death. Increasing evidence has accumulated that gut-derived factors play a crucial role in the development and progression of chronic liver diseases.

methodsA selective literature search was conducted in Medline and PubMed, using the terms "nonalcoholic fatty liver disease," "alcoholic liver disease," "lipopolysaccharide," "gut barrier," and "microbiome."

resultsGut dysbiosis and gut barrier dysfunction both contribute to chronic liver disease by abnormal regulation of the gut-liver axis. Thereby, gut-derived lipopolysaccharides (LPS) are a key factor in inducing the inflammatory response of liver tissue. The review further underlines that endotoxemia is observed in both NAFLD and ALD patients. LPS plays an important role in conducting liver damage through the LPS-TLR4 signaling pathway. Treatments targeting the gut microbiome and the gut barrier such as fecal microbiota transplantation (FMT), probiotics, prebiotics, synbiotics, and intestinal alkaline phosphatase (IAP) represent potential treatment modalities for NAFLD and ALD.

conclusionsThe gut-liver axis plays an important role in the development of liver disease. Treatments targeting the gut microbiome and the gut barrier have shown beneficial effects in attenuating liver inflammation and need to be further investigated.

Indexed as

Gastrointestinal MicrobiomeLiver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseDysbiosisHumansLipopolysaccharidesLiverLipopolysaccharidesALDGut barrierLPSMicrobiomeNAFLD

Identifiers

PMID34734369
PMCPMC8926958
OpenAlexW3208249635

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.